Category Archives: Latanoprost

Dermaliq Therapeutics DLQ01 Prostaglandin F2α Analogue Topical




Dermaliq Logo

Dermaliq Therapeutics DLQ01: Phase 2 Clinical Trials Successful

I first mentioned Dermaliq Therapeutics in a 2022 update to my 2020 post on increasing prostaglandin E2 (PGE2) and prostaglandin F2α (also called PGF2α or PGF2 alpha) for hair growth. The US-based privately-held company is working on a topical Prostaglandin F2α analogue hair growth product called DLQ01 (thought to contain latanoprost). It is based on Dermaliq’s novel and proprietary platform technology called hyliQ®.

The company claims that hyliQ “offers cutaneous drug delivery with unmatched bioavailability for a wide range of pharmaceutical actives”. In 2022, Dermaliq started Phase 1b/2a clinical trials for DLQ01 at Sinclair Dermatology in Melbourne, Australia. This clinic is run by the renowned dermatologist Dr. Rodney Sinclair, who I have written about numerous times in the past.

Dermaliq Therapeutics DLQ01
Dermaliq Therapeutics DLQ01 topical formulation of a prostaglandin F2α analog in hyliQ®.

Earlier today, reader “John Doe” found an update on Dermaliq’s pipeline page which suggests that Phase 2 trials are finished and the results were very good. See the above screenshot. It says the following:

“DLQ01 Phase 2 data has impressively demonstrated its superior efficacy. The number of hairs in the target area increased effectively with high statistical significance compared to the vehicle. More than 80% of subjects responded with a positive change in hair growth. We are continuing clinical development based on a clear regulatory pathway to approval.”

To me, this signals that Phase 3 clinical trials are now a certainty. The company’s news page has not been updated since December 2022, but I suspect that this will change soon.

Note that DLQ01 is said to grow hair in both men and women suffering from androgenetic alopecia (aka male and female pattern baldness). According to Dr. Betsy Hughes-Formella (Chief Scientific Officer at Dermaliq):

“Dermaliq’s hyliQ® technology has the potential to transform follicular and dermal delivery of a broad range of active ingredients. DLQ01 is just the start of a promising pipeline targeting follicular delivery.”

Prostaglandin F2α Analogue Latanoprost

Prostaglandin F2α analogue Latanoprost has already proven to grow eyelash hair longer and thicker. Latanoprost (brand name Xalatan) is a medication that is meant to be used to treat glaucoma  and hypertension in the eyes. It was approved for medical use in the US in 1996. The eyelash hair growth (and darkening) was a notable side effect.

Several companies are developing combination hair growth products based on Latanoprost. The most promising of these is Triple Hair (Canada), which is on the verge of commencing Phase 3 clinical trials. Another company called Aneira Pharma (US) does not seem to have updated it website for several years. However, the company’s hair growth related patent applications are still being updated as of 2024 (h/t “John Doe”).

Triple Hair Therapy-07 Phase 3 Clinical Trials Soon

Triple Hair is a Canadian biotechnology company that is developing new topical treatments for men and women who suffer from androgenic alopecia. A number of people have mentioned this company in the comments in recent years.

Triple Hair
Triple Hair Logo.

Triple Hair: Therapy-07 for Hair Growth

Triple Hair’s main product is a prescription triple combination topical called Therapy-07. It contains minoxidil, finasteride and latanoprost (a prostaglandin F2α analog). It is currently sold via Texas-based Pharmacy Solutions.

When I first read about Therapy-07, while it seemed interesting, it did not sound like anything special to me. The reason is because we are now spoiled for choice when it comes to online purchase options of topical finasteride containing hair loss products that also include minoxidil and other key ingredients.

  • In fact HairStim (US) already makes a product that contains minoxidil, finasteride and latanoprost. As well as other combinations that include spironolactone and resveratrol.
  • Another US-based company named Aneira Pharma is working a product that includes latanoprost, minoxidil and various other ingredients.
  • Dermaliq (US) is preparing for Phase clinical trials for its prostaglandin F2α analogue topical hair growth product DLQ01 that is thought to contain latanoprost.

Phase 3 Clinical Trial Approvals in Europe and Canada

However, today I changed my mind slightly after reader “John Doe” e-mailed me to notify that Triple Hair has just received EMA approval to start phase III clinical trials for its Therapy-07 prescription drug in Europe.

Do note that in June 2023, Triple Hair already received approval to begin phase III clinical trials in Canada. At the time, company CEO Jean-Philippe Gravel said that they were also awaiting similar approvals in the US and Europe. As soon as all approvals are obtained they planned to begin the final trials.

So far, among the many companies selling topical finasteride for hair loss, only Almirall (Spain) has gone through the entire three stage clinical trial process. The expenses to go through three trials for a topical hair loss porduct is generally not justifiable to investors. Especially with key ingredients such as finasteride and minoxidil.

Therapy-16

Triple Hair also sells an over-the-counter hair loss product called Therapy-16. For men, it is sold via the brand name Rizn. It is a drug-free once a day formula that is made with natural ingredients. They sell a RIZN Hair Density Spray and RIZN Hair Complex pills. The woman’s Therapy-16 Hair Densifying Spray product goes by the brand name Plenty Natural. Is contains Japanese knotweed, melatonin and peasprout extracts.

Interestingly, the company claims that these products reduce Prostaglandin D2 (PGD2) levels, which aid hair growth. I discussed the positive impact of decreasing PGD2 on hair growth in several posts in the past. However, I am skeptical about how big an impact natural products can have on scalp PGD2 levels.